The world has not yet recovered from the Covid-19 pandemic, a new outbreak is causing fears. There are still widespread lockdowns going on in China
On March 28, Tonix Pharmaceutical Holding Corp. (TNXP) after trading in the red during regular trading, rebounded in the after hours. This rebound in the
Tonix Pharmaceuticals Holding Corp. (TNXP) is a leading global biotherapeutics company focused on the development of therapeutics for different unmet medical conditions. The company’s leading
Tonix Pharmaceuticals Holding Corp. (TNXP) is a biotherapeutics company engaged in the discovery, licensing, acquisition, and development of therapeutics for different diseases. The company’s product
TNXP stock closed Friday, July 23, 2021 at $0.98. Earlier in the morning session on Monday, TNXP shares lost 34.18% at $0.64. Tonix Pharmaceuticals Holding
In premarket trading session, Tonix Pharmaceuticals Holding Corp. (TNXP) stock had surged by 2.46% to $1.25 at last check. TNXP stock previously closed the session at
Tonix Pharmaceuticals Inc. (NASDAQ: TNXP) stock declined by 8.67% in the last trading close, whereas the TNXP stock price rises by 6.57% during pre-market after
Tonix has licensed technology from the French National Institute of Health and Medical Research (Inserm). Shares of Tonix Pharmaceuticals (TNXP) have since the start of
The US stock indexes were traded in small ranges on January 12. The S&P 500 has risen symbolically by 0.04% to 3801 points, with the
Key US stock index futures are mostly lower on Wednesday, while traders await the results of the US Senate elections and the announcement of the
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.